Efficacy and pharmacogenomic correlation of the combination of oxaliplatin and paclitaxel in first line advanced non-small cell lung cancer (NSCLC). Preliminary results of the Spanish Lung Cancer Group (SLCG) 0103 phase II trial

P. Garrido Lopez,Dolores Isla,B. Gil,M. López-Brea,P. Lianes,J.L. González Larriba,B. Medina,M. Sanchez Ronco,M. Taron,R. Rosell

Efficacy and pharmacogenomic correlation of the combination of oxaliplatin and paclitaxel in first line advanced non-small cell lung cancer (NSCLC). Preliminary results of the Spanish Lung Cancer Group (SLCG) 0103 phase II trial

2006

P. Garrido Lopez
Dolores Isla
B. Gil
M. López-Brea
P. Lianes
J.L. González Larriba
B. Medina
M. Sanchez Ronco
M. Taron
R. Rosell

7122 Background: Ox is an attractive platinum analogue that has not been fully explored in NSCLC. We tested the combination of ox/pac as first-line therapy in NSCLC. We also assessed single nucleot...

Keywords:

non-small cell lung cancer (NSCLC)
Pharmacogenomics
Paclitaxel
Cancer research
Lung cancer
Medicine
Oncology
Oxaliplatin
Internal medicine
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations